ASE Technology Holding Co Ltd vs BIO-TECHNE Corp — how do they compare? ASE Technology Holding Co Ltd trades at $38.7 (market cap $101.68B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: ASE Technology Holding Co Ltd is far larger — about 9× BIO-TECHNE Corp's market cap, and ASE Technology Holding Co Ltd pays the higher dividend (1.11%). Which is the better fit depends on your goals.
| ASX | TECH | |
|---|---|---|
Market Cap | $101.68B | $11.24B |
Sector | Technology | Health |
52-Week High | $45.12 | $72.29 |
52-Week Low | $9.63 | $43.31 |
Enterprise Value | $106.08B | $11.32B |
Dividend Yield | 1.11% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $37.39, up 0.38% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.29, beating estimates of $0.23, and announced a $10.5 billion capital expenditure increase for AI-driven growth (Reuters, July 30, 2026). Revenue rose to $645.39 billion in 2025, with net income of $40.02 billion, while valuation ratios like P/E of 46.26 suggest premium pricing.
Outlook remains positive due to AI semiconductor demand and margin expansion, but risks include high valuation and competitive pressures. Analysts are largely bullish with 80% buy ratings, though the stock faces volatility near resistance at $38.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →